These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 29546738)

  • 1. Multidimensional Prognostic Index and pro-adrenomedullin plasma levels as mortality risk predictors in older patients hospitalized with community-acquired pneumonia: a prospective study.
    Pilotto A; Dini S; Veronese N; Daragjati J; Miolo M; Mion MM; Fontana A; Lo Storto M; Zaninotto M; Bragato G; Cella A; Carraro P; Addante F; Copetti M; Plebani M
    Panminerva Med; 2018 Sep; 60(3):80-85. PubMed ID: 29546738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined use of the multidimensional prognostic index (MPI) and procalcitonin serum levels in predicting 1-month mortality risk in older patients hospitalized with community-acquired pneumonia (CAP): a prospective study.
    Pilotto A; Dini S; Daragjati J; Miolo M; Mion MM; Fontana A; Storto ML; Zaninotto M; Cella A; Carraro P; Addante F; Copetti M; Plebani M
    Aging Clin Exp Res; 2018 Feb; 30(2):193-197. PubMed ID: 28417242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Red blood cell distribution width [RDW] and long-term mortality after community-acquired pneumonia. A comparison with proadrenomedullin.
    Bello S; Fandos S; Lasierra AB; Mincholé E; Panadero C; Simon AL; Gavin O; De Pablo F; Menendez R; Torres A
    Respir Med; 2015 Sep; 109(9):1193-206. PubMed ID: 26205553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia.
    Courtais C; Kuster N; Dupuy AM; Folschveiller M; Jreige R; Bargnoux AS; Guiot J; Lefebvre S; Cristol JP; Sebbane M
    Am J Emerg Med; 2013 Jan; 31(1):215-21. PubMed ID: 23000327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.
    España PP; Capelastegui A; Mar C; Bilbao A; Quintana JM; Diez R; Esteban C; Bereciartua E; Unanue U; Uranga A
    J Infect; 2015 May; 70(5):457-66. PubMed ID: 25499199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397].
    Christ-Crain M; Morgenthaler NG; Stolz D; Müller C; Bingisser R; Harbarth S; Tamm M; Struck J; Bergmann A; Müller B
    Crit Care; 2006; 10(3):R96. PubMed ID: 16805922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia.
    Huang DT; Angus DC; Kellum JA; Pugh NA; Weissfeld LA; Struck J; Delude RL; Rosengart MR; Yealy DM
    Chest; 2009 Sep; 136(3):823-831. PubMed ID: 19363212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with community-acquired pneumonia: a systematic review and meta-analysis.
    Liu D; Xie L; Zhao H; Liu X; Cao J
    BMC Infect Dis; 2016 May; 16():232. PubMed ID: 27230573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia.
    Suberviola B; Castellanos-Ortega A; Llorca J; Ortiz F; Iglesias D; Prieto B
    Swiss Med Wkly; 2012; 142():w13542. PubMed ID: 22430899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of midregional proadrenomedullin to predict poor outcome in patients with community acquired pneumonia.
    Gordo-Remartínez S; Calderón-Moreno M; Fernández-Herranz J; Castuera-Gil A; Gallego-Alonso-Colmenares M; Puertas-López C; Nuevo-González JA; Sánchez-Sendín D; García-Gámiz M; Sevillano-Fernández JA; Álvarez-Sala LA; Andueza-Lillo JA; de Miguel-Yanes JM
    PLoS One; 2015; 10(6):e0125212. PubMed ID: 26030588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?
    Pereira JM; Azevedo A; Basílio C; Sousa-Dias C; Mergulhão P; Paiva JA
    Rev Port Pneumol (2006); 2016; 22(6):308-314. PubMed ID: 27160747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reliability of Pro-adrenomedullin and Interleukin 1β in Predicting Severity of Community-Acquired Pneumonia in Pediatric Patients.
    Korkmaz MF; Güzel A; Açıkgöz M; Okuyucu A; Alaçam H
    Ann Clin Lab Sci; 2018 Jan; 48(1):81-89. PubMed ID: 29531001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proadrenomedullin improves Risk of Early Admission to ICU score for predicting early severe community-acquired pneumonia.
    Renaud B; Schuetz P; Claessens YE; Labarère J; Albrich W; Mueller B
    Chest; 2012 Dec; 142(6):1447-1454. PubMed ID: 22661450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pro-adrenomedullin usefulness in the management of children with community-acquired pneumonia, a preliminar prospective observational study.
    Sardà Sánchez M; Hernández JC; Hernández-Bou S; Teruel GC; Rodríguez JV; Cubells CL
    BMC Res Notes; 2012 Jul; 5():363. PubMed ID: 22818355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic performance of MR-pro-adrenomedullin in patients with community acquired pneumonia in the Emergency Department compared to clinical severity scores PSI and CURB.
    Legramante JM; Mastropasqua M; Susi B; Porzio O; Mazza M; Miranda Agrippino G; D Agostini C; Brandi A; Giovagnoli G; Di Lecce VN; Bernardini S; Minieri M
    PLoS One; 2017; 12(11):e0187702. PubMed ID: 29161297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology.
    Bello S; Lasierra AB; Mincholé E; Fandos S; Ruiz MA; Vera E; de Pablo F; Ferrer M; Menendez R; Torres A
    Eur Respir J; 2012 May; 39(5):1144-55. PubMed ID: 22075489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Midregional proadrenomedullin for prognosis in community-acquired pneumonia: a systematic review.
    Cavallazzi R; El-Kersh K; Abu-Atherah E; Singh S; Loke YK; Wiemken T; Ramirez J
    Respir Med; 2014 Nov; 108(11):1569-80. PubMed ID: 25448309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short- and longer-term predictive capacity of the Multidimensional Prognostic Index: The timing of the assessment is of no consequence.
    De Luca E; Perissinotto E; Fabris L; Pengo V; Zurlo A; De Toni P; De Zaiacomo F; Manzato E; Giantin V
    Arch Gerontol Geriatr; 2015; 61(3):458-63. PubMed ID: 26306454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ.
    Krüger S; Ewig S; Giersdorf S; Hartmann O; Suttorp N; Welte T;
    Am J Respir Crit Care Med; 2010 Dec; 182(11):1426-34. PubMed ID: 20639437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The multidimensional prognostic index predicts short- and long-term mortality in hospitalized geriatric patients with pneumonia.
    Pilotto A; Addante F; Ferrucci L; Leandro G; D'Onofrio G; Corritore M; Niro V; Scarcelli C; Dallapiccola B; Franceschi M
    J Gerontol A Biol Sci Med Sci; 2009 Aug; 64(8):880-7. PubMed ID: 19349589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.